36576155|t|Plasma glial fibrillary acidic protein in autosomal dominant Alzheimer's disease: Associations with Abeta-PET, neurodegeneration, and cognition.
36576155|a|BACKGROUND: Glial fibrillary acidic protein (GFAP) is a promising candidate blood-based biomarker for Alzheimer's disease (AD) diagnosis and prognostication. The timing of its disease-associated changes, its clinical correlates, and biofluid-type dependency will influence its clinical utility. METHODS: We evaluated plasma, serum, and cerebrospinal fluid (CSF) GFAP in families with autosomal dominant AD (ADAD), leveraging the predictable age at symptom onset to determine changes by stage of disease. RESULTS: Plasma GFAP elevations appear a decade before expected symptom onset, after amyloid beta (Abeta) accumulation and prior to neurodegeneration and cognitive decline. Plasma GFAP distinguished Abeta-positive from Abeta-negative ADAD participants and showed a stronger relationship with Abeta load in asymptomatic than symptomatic ADAD. Higher plasma GFAP was associated with the degree and rate of neurodegeneration and cognitive impairment. Serum GFAP showed similar relationships, but these were less pronounced for CSF GFAP. CONCLUSION: Our findings support a role for plasma GFAP as a clinical biomarker of Abeta-related astrocyte reactivity that is associated with cognitive decline and neurodegeneration. HIGHLIGHTS: Plasma glial fibrillary acidic protein (GFAP) elevations appear a decade before expected symptom onset in autosomal dominant Alzheimer's disease (ADAD). Plasma GFAP was associated to amyloid positivity in asymptomatic ADAD. Plasma GFAP increased with clinical severity and predicted disease progression. Plasma and serum GFAP carried similar information in ADAD, while cerebrospinal fluid GFAP did not.
36576155	7	38	glial fibrillary acidic protein	Gene	2670
36576155	42	80	autosomal dominant Alzheimer's disease	Disease	MESH:D000544
36576155	100	105	Abeta	Gene	351
36576155	111	128	neurodegeneration	Disease	MESH:D019636
36576155	157	188	Glial fibrillary acidic protein	Gene	2670
36576155	190	194	GFAP	Gene	2670
36576155	247	266	Alzheimer's disease	Disease	MESH:D000544
36576155	268	270	AD	Disease	MESH:D000544
36576155	507	511	GFAP	Gene	2670
36576155	529	550	autosomal dominant AD	Disease	MESH:D000544
36576155	552	556	ADAD	Disease	MESH:D000544
36576155	665	669	GFAP	Gene	2670
36576155	734	746	amyloid beta	Gene	351
36576155	748	753	Abeta	Gene	351
36576155	781	798	neurodegeneration	Disease	MESH:D019636
36576155	803	820	cognitive decline	Disease	MESH:D003072
36576155	829	833	GFAP	Gene	2670
36576155	848	853	Abeta	Gene	351
36576155	868	873	Abeta	Gene	351
36576155	883	887	ADAD	Disease	MESH:D000544
36576155	941	946	Abeta	Gene	351
36576155	985	989	ADAD	Disease	MESH:D000544
36576155	1005	1009	GFAP	Gene	2670
36576155	1053	1070	neurodegeneration	Disease	MESH:D019636
36576155	1075	1095	cognitive impairment	Disease	MESH:D003072
36576155	1103	1107	GFAP	Gene	2670
36576155	1177	1181	GFAP	Gene	2670
36576155	1234	1238	GFAP	Gene	2670
36576155	1266	1271	Abeta	Gene	351
36576155	1325	1342	cognitive decline	Disease	MESH:D003072
36576155	1347	1364	neurodegeneration	Disease	MESH:D019636
36576155	1385	1416	glial fibrillary acidic protein	Gene	2670
36576155	1418	1422	GFAP	Gene	2670
36576155	1484	1522	autosomal dominant Alzheimer's disease	Disease	MESH:D000544
36576155	1524	1528	ADAD	Disease	MESH:D000544
36576155	1538	1542	GFAP	Gene	2670
36576155	1561	1568	amyloid	Disease	MESH:C000718787
36576155	1596	1600	ADAD	Disease	MESH:D000544
36576155	1609	1613	GFAP	Gene	2670
36576155	1699	1703	GFAP	Gene	2670
36576155	1735	1739	ADAD	Disease	MESH:D000544
36576155	1767	1771	GFAP	Gene	2670
36576155	Association	MESH:D000544	351
36576155	Association	MESH:C000718787	2670
36576155	Association	MESH:D019636	351
36576155	Association	MESH:D000544	2670
36576155	Association	2670	351
36576155	Association	MESH:D019636	2670
36576155	Positive_Correlation	MESH:D003072	2670

